Home » Stocks » EVOK

Evoke Pharma, Inc. (EVOK)

Stock Price: $3.08 USD -0.10 (-3.14%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $3.05 -0.03 (-0.97%) Dec 3, 5:49 PM

EVOK Stock Price Chart

Key Info

Market Cap 81.28M
Revenue (ttm) n/a
Net Income (ttm) -12.31M
Shares Out 26.15M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $3.08
Previous Close $3.18
Change ($) -0.10
Change (%) -3.14%
Day's Open 3.21
Day's Range 3.05 - 3.21
Day's Volume 105,036
52-Week Range 0.82 - 5.70

EVOK Stock News

GlobeNewsWire - 3 weeks ago

Gimoti™ commercial launch underway

GlobeNewsWire - 1 month ago

Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis Product launch provides healthcare pr...

GlobeNewsWire - 2 months ago

SOLANA BEACH, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...

GlobeNewsWire - 3 months ago

Gimoti commercial launch on track for the fourth quarter of 2020 Gimoti commercial launch on track for the fourth quarter of 2020

GlobeNewsWire - 3 months ago

Preparing for commercial launch of GIMOTI™ in 4Q 2020 Preparing for commercial launch of GIMOTI™ in 4Q 2020

GlobeNewsWire - 4 months ago

Preparing commercial launch of GIMOTI™ in 4Q 2020 Preparing commercial launch of GIMOTI™ in 4Q 2020

GlobeNewsWire - 4 months ago

Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020 Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020

Kiplinger - 5 months ago

Cheap stocks are effectively Wall Street's casino.

Other stocks mentioned: AIM, IBIO, LIVX
InvestorPlace - 5 months ago

Evoke Pharma received a nod of approval from the U.S. Food and Drug Administration, and investors can now have confidence in EVOK stock.

Benzinga - 5 months ago

Last Friday was my 56th consecutive green day of trading and I ended up ending it with a gross profit of $225,000, which easily blows past the $1 million mark for the streak and is several mag...

Other stocks mentioned: FRAN, NEON, SINT
24/7 Wall Street - 5 months ago

In an update provided over the weekend, Evoke Pharma Inc. (NASDAQ: EVOK) said that the U.S.

Benzinga - 5 months ago

The binary event that was scheduled for last week panned out in favor of Evoke Pharma Inc (NASDAQ: EVOK).

GlobeNewsWire - 5 months ago

Commercial Partner EVERSANA Prepares for GIMOTI Launch Evoke Extends Cash Runway into 2021

GlobeNewsWire - 6 months ago

SOLANA BEACH, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today a...

GlobeNewsWire - 8 months ago

Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020 Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020

GlobeNewsWire - 10 months ago

SOLANA BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...

GlobeNewsWire - 10 months ago

EVERSANA to commercialize and distribute Gimoti in the U.S.

Zacks Investment Research - 10 months ago

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

GlobeNewsWire - 10 months ago

PDUFA Target Goal Date is June 19, 2020 PDUFA Target Goal Date is June 19, 2020

GlobeNewsWire - 11 months ago

SOLANA BEACH, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...

GlobeNewsWire - 1 year ago

SOLANA BEACH, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...

GlobeNewsWire - 1 year ago

SOLANA BEACH, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...

GlobeNewsWire - 1 year ago

SOLANA BEACH, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...

Benzinga - 1 year ago

Evoke Pharma, Inc. (NASDAQ: EVOK) shares have lost about 51% of their value year to date compared to the 9.4%-gain in the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) and a steeper 20% jum...

Zacks Investment Research - 1 year ago

During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

About EVOK

Evoke Pharma, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.... Full company profile.

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Sep 25, 2013
CEO
David Gonyer
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
EVOK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Evoke Pharma stock is "Buy." The 12-month stock price forecast is 9.50, which is an increase of 208.44% from the latest price.

Price Target
$9.50
(208.44% upside)
Analyst Consensus: Buy